ASLN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients...

Stats
Dzisiejszy wolumen	292 541
Średni wolumen	1.27M
Kapitalizacja rynkowa	7.87M
EPS	$-0.780 ( 2024-05-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.00900 (1.96%)

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: 0.47 (neutral)

Signal:(56.888) Neutral

ASLAN Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
TYRA	0.946
RCEL	0.946
SHIP	0.943
ASUR	0.943
XLRN	0.942
OPRA	0.94
AMPH	0.939
RDNT	0.934
FLMN	0.934
LFMDP	0.933

10 Najbardziej negatywne korelacje
GOODN	-0.944
WISH	-0.943
TBIO	-0.935
TREE	-0.934
UPLD	-0.931
MICS	-0.929
GMVD	-0.927
AVGR	-0.925
BAND	-0.925
GOODO	-0.924

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ASLAN Pharmaceuticals Korelacja - Waluta/Towar

-0.16
( neutral )

0.21
( neutral )

0.00
( neutral )

0.49
( neutral )

ASLAN Pharmaceuticals Finanse

Annual	2023
Przychody:	$12.00M
Zysk brutto:	$11.65M (97.10 %)
EPS:	$-2.69

FY	2023
Przychody:	$12.00M
Zysk brutto:	$11.65M (97.10 %)
EPS:	$-2.69

FY	2022
Przychody:	$0
Zysk brutto:	$-331 752 (0.00 %)
EPS:	$-3.68

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.815

Financial Reports:

No articles found.

ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.